Distribution of equivalent orphan drugs
Pharmaceutical robot ChemoMaker®
Biosimilars and APIs
Between 2024 and 2025, BIP won seven three-year regional hospital tenders for the distribution of Miglustat (GenOrph) to public hospitals (tender amount +€400k/year) and is a supplier to private hospitals throughout the country.
In 2025, an agreement was also signed for the distribution of a new orphan drug, iBugo, with commercial launch beginning in the second half of 2025 (five tenders already awarded in 2025, for a total value of €2.2 million/year).
Operational details:
The ChemoMaker® pharmaceutical robot is the first innovation developed by the group. It is the only pharmaceutical robot that does not require infrastructure modifications in hospital pharmacies while offering the same performance, and the only robot that can handle Baxter multi-dose preparation bags. The technology is patented in the European Union, the United States, and China, protecting key markets. As of September 2025, 23 devices have been sold to distributors, 5 of which have already been installed in Italian hospitals. In 2025, the closed-circuit CSTD version of ChemoMaker® was launched, compatible with Becton Dickinson cartridges.
The business model has three revenue streams:
Sale of ChemoMaker® (una tantum)
1.Sale of patented cartridges compatible with various CSTDs (recurring)
1.Technical support and software license (recurring)
In 2020, BIP launched an ambitious Deep Tech project with Serichim (85.5% owned) to develop insulin biosimilars. Serichim has created a dedicated biotechnology team and entered into a strategic agreement with the ICGEB (International Centre for Genetic Engineering and Biotechnology) for the transfer of know-how on the production of insulin biosimilars, including slow-release ones such as Degludec.
In fact, the expiry of patents for the latest generation of insulins (Degludec, Tresiba) opens up an extraordinary window of opportunity: a global market worth 8.3 billion by 2030. The Serichim-ICGEB platform puts the BIP group in a position to capitalize on this opportunity with European know-how and local production.
Milestones achieved:
Serichim has also built up a portfolio of nine patents that protect the Group’s innovations in the fields of biotechnology, chemical processes, and API (Active Pharmaceutical Ingredients) production.
In 2023, Serichim patented a device for dynamic hydrogen release (DHR) that attracted the interest of major players such as Fincantieri and won a €1 million EU project for its development.
In October 2025, LOHCATE SRL was founded, a company to which Serichim’s hydrogen business unit will be transferred in order to enable the rapid development of this branch of the energy and environment sector, which also has a broader impact on health.